Multi-Organ Transplant Program, London Health Sciences Centre, University Hospital, London, ON, Canada.
Transplantation. 2011 Sep 27;92(6):686-9. doi: 10.1097/TP.0b013e31822a79d2.
In hepatitis C virus (HCV) recipients of donation after cardiac death (DCD) grafts, there is suggestion of lower rates of graft survival, indicating that DCD grafts themselves may represent a significant risk factor for severe recurrence of HCV.
We evaluated all DCD liver transplant recipients from August 2006 to February 2011 at our center. Recipients with HCV who received a DCD graft (group 1, HCV+ DCD, n=17) were compared with non-HCV recipients transplanted with a DCD graft (group 2, HCV- DCD, n=15), and with a matched group of HCV recipients transplanted with a donation after brain death (DBD) graft (group 3, HCV+ DBD, n=42).
A trend of poorer graft survival was seen in HCV+ patients who underwent a DCD transplant (group 1) compared with HCV- patients who underwent a DCD transplant (group 2) (P=0.14). Importantly, a statistically significant difference in graft survival was seen in HCV+ patients undergoing DCD transplant (group 1) (73%) as compared with DBD transplant (group 3) (93%)(P=0.01). There was a statistically significant increase in HCV recurrence at 3 months (76% vs. 16%) (P=0.005) and severe HCV recurrence within the first year (47% vs. 10%) in the DCD group (P=0.004).
HCV recurrence is more severe and progresses more rapidly in HCV+ recipients who receive grafts from DCD compared with those who receive grafts from DBD. DCD liver transplantation in HCV+ recipients is associated with a higher rate of graft failure compared with those who receive grafts from DBD. Caution must be taken when using DCD grafts in HCV+ recipients.
在接受心脏死亡供体(DCD)移植物的丙型肝炎病毒(HCV)受者中,移植物存活率较低,这表明 DCD 移植物本身可能是 HCV 严重复发的一个重要危险因素。
我们评估了 2006 年 8 月至 2011 年 2 月期间在我们中心接受 DCD 肝移植的所有患者。接受 DCD 移植物的 HCV 受者(第 1 组,HCV+DCD,n=17)与未感染 HCV 但接受 DCD 移植物的受者(第 2 组,HCV-DCD,n=15)进行比较,并与接受脑死亡供体(DBD)移植物的 HCV 受者匹配组(第 3 组,HCV+DBD,n=42)进行比较。
与接受 DCD 移植的未感染 HCV 受者(第 2 组)相比,接受 DCD 移植的 HCV 阳性受者(第 1 组)的移植物存活率呈下降趋势(P=0.14)。重要的是,接受 DCD 移植的 HCV 阳性患者(第 1 组)的移植物存活率与 DBD 移植患者(第 3 组)(93%)相比有显著差异(P=0.01)(73%)。DCD 组 HCV 复发率在 3 个月时(76%比 16%)(P=0.005)和第 1 年内(47%比 10%)有显著增加(P=0.004)。
与接受 DBD 移植物的受者相比,HCV+受者接受 DCD 移植物后 HCV 复发更严重,进展更快。与接受 DBD 移植物的受者相比,HCV+受者接受 DCD 肝移植后移植物失败的发生率更高。在 HCV+受者中使用 DCD 移植物时必须谨慎。